NCT07027124
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07027124
Title Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Recruitment Not yet recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Icahn School of Medicine at Mount Sinai
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.